Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
CELG
Celgene Corp
CELG
|
+$656M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$612M |
| 3 |
Biogen
BIIB
|
+$405M |
| 4 |
UnitedHealth
UNH
|
+$353M |
| 5 |
Walmart
WMT
|
+$316M |
Top Sells
| 1 |
Apple
AAPL
|
+$483M |
| 2 |
PepsiCo
PEP
|
+$394M |
| 3 |
RHT
Red Hat Inc
RHT
|
+$248M |
| 4 |
Philip Morris
PM
|
+$246M |
| 5 |
Eli Lilly
LLY
|
+$240M |
Sector Composition
| 1 | Healthcare | 18.91% |
| 2 | Technology | 12.35% |
| 3 | Consumer Discretionary | 10.31% |
| 4 | Financials | 9.99% |
| 5 | Consumer Staples | 8.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3076
Arbutus Biopharma
ABUS
$849M
| $257K | ﹤0.01% |
168,312
-9,888
| -6% | -$15.1K |
|
|
RRD
3077
DELISTED
RR Donnelley & Sons Co.
RRD
| $257K | ﹤0.01% |
68,093
+37,893
| +125% | +$143K |
|
3078
iShares Agency Bond ETF
AGZ
$618M
| $256K | ﹤0.01% |
2,200
-3,100
| -58% | -$361K |
|
3079
Forte Biosciences
FBRX
$149M
| $256K | ﹤0.01% |
1,030
+952
| +1,221% | +$237K |
|
3080
Soligenix
SNGX
$12M
| $256K | ﹤0.01% |
1,125
+167
| +17% | +$38K |
|
3081
First Trust NASDAQ-100 Technology Index Fund
QTEC
$2.78B
| $254K | ﹤0.01% |
+2,900
| New | +$254K |
|
3082
BioLife Solutions
BLFS
$1.23B
| $254K | ﹤0.01% |
15,300
-105,300
| -87% | -$1.75M |
|
3083
Federated Hermes
FHI
$4.08B
| $253K | ﹤0.01% |
+7,800
| New | +$253K |
|
|
MNTX
3084
DELISTED
Manitex International, Inc.
MNTX
| $253K | ﹤0.01% |
38,040
-45,000
| -54% | -$299K |
|
3085
iShares Core 60/40 Balanced Allocation ETF
AOR
$2.78B
| $252K | ﹤0.01% |
5,467
-4,700
| -46% | -$217K |
|
3086
Kornit Digital
KRNT
$633M
| $249K | ﹤0.01% |
+8,100
| New | +$249K |
|
3087
Fortress Biotech
FBIO
$102M
| $249K | ﹤0.01% |
11,775
+10,673
| +969% | +$226K |
|
3088
SPDR S&P MidCap 400 ETF Trust
MDY
$23.8B
| $247K | ﹤0.01% |
700
-1,200
| -63% | -$423K |
|
|
BLU
3089
DELISTED
BELLUS Health Inc.
BLU
| $247K | ﹤0.01% |
+38,438
| New | +$247K |
|
3090
Live Oak Bancshares
LOB
$1.66B
| $243K | ﹤0.01% |
+13,400
| New | +$243K |
|
3091
iShares MSCI Turkey ETF
TUR
$172M
| $243K | ﹤0.01% |
+9,100
| New | +$243K |
|
3092
Taylor Devices
TAYD
$148M
| $242K | ﹤0.01% |
23,600
+1,900
| +9% | +$19.5K |
|
|
NVIV
3093
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
| $241K | ﹤0.01% |
642
+59
| +10% | +$22.1K |
|
|
TSRI
3094
DELISTED
TSR Inc. New
TSRI
| $240K | ﹤0.01% |
75,150
+400
| +0.5% | +$1.28K |
|
3095
WisdomTree US LargeCap Dividend Fund
DLN
$5.33B
| $238K | ﹤0.01% |
4,800
-2,000
| -29% | -$99.2K |
|
3096
Eledon Pharmaceuticals
ELDN
$146M
| $237K | ﹤0.01% |
21,235
-1,513
| -7% | -$16.9K |
|
3097
Matsons
MATX
$3.37B
| $236K | ﹤0.01% |
+6,300
| New | +$236K |
|
|
YTEN
3098
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
| $236K | ﹤0.01% |
489
-9
| -2% | -$4.34K |
|
3099
Soleno Therapeutics
SLNO
$2.71B
| $235K | ﹤0.01% |
10,425
+898
| +9% | +$20.2K |
|
3100
Plumas Bancorp
PLBC
$301M
| $234K | ﹤0.01% |
11,600
+200
| +2% | +$4.03K |
|